📰 Regulatory Sciences News
Page 3 - Regulatory Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Regulatory Sciences. Real-time updates on events, politics, business and more.
September 7, 2022
Washington, DC (PRWEB) September 07, 2022 -- NDA Partners’ General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory
August 16, 2022
Washington, DC (PRWEB) August 16, 2022 -- NDA Partners’ General Manager, Eric Fish, announced today thatBrian Tseng, MD, PhD, a board-certified pediatric
July 26, 2022
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads to the loss of everyday functions and is uniformly fatalIf approved, tofersen would be
July 26, 2022
26.07.2022 - SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads to the loss of everyday functions and is uniformly fatalIf approved, tofersen would be the first treatment to target a genetic cause ... Seite 1
January 28, 2022
Cambridge, MA, Jan 28, 2022 - (JCN Newswire) - Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM
January 27, 2022
CAMBRIDGE, Mass., Jan. 27, 2022Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM (aducanumab-avwa)
December 17, 2021
WESTON (dpa-AFX) - Biogen Inc. (BIIB), an American company focused on the therapies for the treatment of neurological diseases said it intends to seek re-examination of negative opinion adopted
December 17, 2021
Biogen to seek re-examination following CHMP negative opinion for aducanumabCAMBRIDGE, Mass., Dec. 17, 2021Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Committee for
December 2, 2021
Sage Therapeutics Inc. and Biogen Inc. released 12-month data showing zuranolone was generally well-tolerated among adults with major depressive disorder. A total of 199 patients received zuranolone 50 mg once per night for 2 weeks as their initial dose in the ongoing phase 3 open-label SHORELINE Study, with potential for 12 months of follow-up. The study is part of the LANDSCAPE clinical program
December 1, 2021
In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or... | December 1, 2021